Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Han Witjes

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Fertility and Sterility|February 13, 2010
Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trialHuman M Fatemi, Janine Oberyé, Biljana Popovic-Todorovic, et al.
Reproductive Biomedicine Online|March 4, 2014
Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trialTonko Mardešič, Bernadette Mannaerts, Mostafa Abuzeid, et al.
Reproductive Biology and Endocrinology : RB&E|September 14, 2013
Clinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulationJohn L Frattarelli, Torbjörn Hillensjö, Frank J Broekmans, et al.
British Journal of Clinical Pharmacology|December 24, 2016
Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancerKathryn Brown, Craig Comisar, Han Witjes, et al.
Human Reproduction (Oxford, England)|June 7, 2014
Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocolFrank J Broekmans, Pierre J M Verweij, Marinus J C Eijkemans, et al.
Clinical Pharmacology and Therapeutics|April 25, 2022
Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II StudyNeeraj Gupta, Anna Largajolli, Han Witjes, et al.
Fertility and Sterility|May 25, 2015
Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilizationRobert Boostanfar, Bruce Shapiro, Michael Levy, et al.
AJOG Global Reports|October 24, 2022
Magnesium sulfate pharmacokinetics after intramuscular dosing in women with preeclampsiaKathleen Brookfield, Hadiza Galadanci, Lihong Du, et al.
Clinical and Translational Science|November 10, 2025
Exposure-Response Analysis of Donidalorsen for the Treatment of Hereditary AngioedemaPratap Singh, Han Witjes, Huub Jan Kleijn, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|March 21, 2012
A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy ratesJie Qiao, Guangxiu Lu, H W Zhang, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Fertility and Sterility|February 13, 2010
Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trialHuman M Fatemi, Janine Oberyé, Biljana Popovic-Todorovic, et al.
Reproductive Biomedicine Online|March 4, 2014
Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trialTonko Mardešič, Bernadette Mannaerts, Mostafa Abuzeid, et al.
Reproductive Biology and Endocrinology : RB&E|September 14, 2013
Clinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulationJohn L Frattarelli, Torbjörn Hillensjö, Frank J Broekmans, et al.
British Journal of Clinical Pharmacology|December 24, 2016
Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancerKathryn Brown, Craig Comisar, Han Witjes, et al.
Human Reproduction (Oxford, England)|June 7, 2014
Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocolFrank J Broekmans, Pierre J M Verweij, Marinus J C Eijkemans, et al.
Clinical Pharmacology and Therapeutics|April 25, 2022
Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II StudyNeeraj Gupta, Anna Largajolli, Han Witjes, et al.
Fertility and Sterility|May 25, 2015
Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilizationRobert Boostanfar, Bruce Shapiro, Michael Levy, et al.
AJOG Global Reports|October 24, 2022
Magnesium sulfate pharmacokinetics after intramuscular dosing in women with preeclampsiaKathleen Brookfield, Hadiza Galadanci, Lihong Du, et al.
Clinical and Translational Science|November 10, 2025
Exposure-Response Analysis of Donidalorsen for the Treatment of Hereditary AngioedemaPratap Singh, Han Witjes, Huub Jan Kleijn, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|March 21, 2012
A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy ratesJie Qiao, Guangxiu Lu, H W Zhang, et al.
Pageof 3